APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Retinal Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-acting Retinal Drugs Market Outlook and Growth Opportunities 2026

23 December 2025204 pages

Choose your research edition.

Industry ResearchLong-acting Retinal Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Retinal Drugs Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Long-acting Retinal Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Retinal Drugs Market Outlook and Growth Opportunities 2026204 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Retinal Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Long-acting Retinal Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-acting Retinal Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-acting Retinal Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-acting Retinal Drugs market include Janssen Pharmaceuticals (Johnson & Johnson), Takeda, Teva Pharmaceutical, Novartis, Merck, Bayer, Alcon Inc., AbbVie Inc. and ThromboGenics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Long-acting Retinal Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-acting Retinal Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-acting Retinal Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Long-acting Retinal Drugs market.

Long-acting Retinal Drugs Segment by Company

Janssen Pharmaceuticals (Johnson & Johnson)

Takeda

Teva Pharmaceutical

Novartis

Merck

Bayer

Alcon Inc.

AbbVie Inc.

ThromboGenics

Regeneron

Oxurion NV

OncoGene Pharmaceuticals

MeiraGTx Limited

F. Hoffmann-La Roche

Bausch Health Co. Inc.

Allergan

Alimera Sciences Inc.

Long-acting Retinal Drugs Segment by Type

Chemically Synthesized Drugs

Biologics

Natural/Nutritional Supplements

Long-acting Retinal Drugs Segment by Application

Hospital

Clinic

Other

Long-acting Retinal Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Long-acting Retinal Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Long-acting Retinal Drugs key companies, revenue, market share, and recent developments.

3. To split the Long-acting Retinal Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Long-acting Retinal Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-acting Retinal Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Long-acting Retinal Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Retinal Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Retinal Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Retinal Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-acting Retinal Drugs industry.

Chapter 3: Detailed analysis of Long-acting Retinal Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Long-acting Retinal Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Long-acting Retinal Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-acting Retinal Drugs Industry Trends Table 2. Long-acting Retinal Drugs Industry Drivers Table 3. Long-acting Retinal Drugs Industry Opportunities and Challenges Table 4. Long-acting Retinal Drugs Industry Restraints Table 5. Global Long-acting Retinal Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-acting Retinal Drugs Revenue Share by Company (2021-2026) Table 7. Global Long-acting Retinal Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Long-acting Retinal Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Long-acting Retinal Drugs Company, Product Type & Application Table 10. Global Long-acting Retinal Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Long-acting Retinal Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Chemically Synthesized Drugs Table 15. Significant Companies of Biologics Table 16. Significant Companies of Natural/Nutritional Supplements Table 17. Global Long-acting Retinal Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Long-acting Retinal Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Long-acting Retinal Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Long-acting Retinal Drugs Sales Value Share by Type (2021-2026) Table 21. Global Long-acting Retinal Drugs Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Clinic Table 24. Significant Companies of Other Table 25. Global Long-acting Retinal Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Long-acting Retinal Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Long-acting Retinal Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Long-acting Retinal Drugs Sales Value Share by Application (2021-2026) Table 29. Global Long-acting Retinal Drugs Sales Value Share by Application (2027-2032) Table 30. Global Long-acting Retinal Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Long-acting Retinal Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Long-acting Retinal Drugs Sales Value Share by Region (2021-2026) Table 33. Global Long-acting Retinal Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Long-acting Retinal Drugs Sales Value Share by Region (2027-2032) Table 35. Global Long-acting Retinal Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Long-acting Retinal Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Long-acting Retinal Drugs Sales Value Market Share by Country (2021-2026) Table 38. Global Long-acting Retinal Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Long-acting Retinal Drugs Sales Value Market Share by Country (2027-2032) Table 40. Janssen Pharmaceuticals (Johnson & Johnson) Company Information Table 41. Janssen Pharmaceuticals (Johnson & Johnson) Business Overview Table 42. Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio Table 44. Janssen Pharmaceuticals (Johnson & Johnson) Recent Development Table 45. Takeda Company Information Table 46. Takeda Business Overview Table 47. Takeda Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Takeda Long-acting Retinal Drugs Product Portfolio Table 49. Takeda Recent Development Table 50. Teva Pharmaceutical Company Information Table 51. Teva Pharmaceutical Business Overview Table 52. Teva Pharmaceutical Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio Table 54. Teva Pharmaceutical Recent Development Table 55. Novartis Company Information Table 56. Novartis Business Overview Table 57. Novartis Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Novartis Long-acting Retinal Drugs Product Portfolio Table 59. Novartis Recent Development Table 60. Merck Company Information Table 61. Merck Business Overview Table 62. Merck Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Merck Long-acting Retinal Drugs Product Portfolio Table 64. Merck Recent Development Table 65. Bayer Company Information Table 66. Bayer Business Overview Table 67. Bayer Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Bayer Long-acting Retinal Drugs Product Portfolio Table 69. Bayer Recent Development Table 70. Alcon Inc. Company Information Table 71. Alcon Inc. Business Overview Table 72. Alcon Inc. Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Alcon Inc. Long-acting Retinal Drugs Product Portfolio Table 74. Alcon Inc. Recent Development Table 75. AbbVie Inc. Company Information Table 76. AbbVie Inc. Business Overview Table 77. AbbVie Inc. Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. AbbVie Inc. Long-acting Retinal Drugs Product Portfolio Table 79. AbbVie Inc. Recent Development Table 80. ThromboGenics Company Information Table 81. ThromboGenics Business Overview Table 82. ThromboGenics Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. ThromboGenics Long-acting Retinal Drugs Product Portfolio Table 84. ThromboGenics Recent Development Table 85. Regeneron Company Information Table 86. Regeneron Business Overview Table 87. Regeneron Long-acting Retinal Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Regeneron Long-acting Retinal Drugs Product Portfolio Table 89. Regeneron Recent Development Table 90. Oxurion NV Company Information Table 91. Oxurion NV Business Overview Table 92. Oxurion NV Long-acting Retinal Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Oxurion NV Long-acting Retinal Drugs Product Portfolio Table 94. Oxurion NV Recent Development Table 95. OncoGene Pharmaceuticals Company Information Table 96. OncoGene Pharmaceuticals Business Overview Table 97. OncoGene Pharmaceuticals Long-acting Retinal Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio Table 99. OncoGene Pharmaceuticals Recent Development Table 100. MeiraGTx Limited Company Information Table 101. MeiraGTx Limited Business Overview Table 102. MeiraGTx Limited Long-acting Retinal Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 103. MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio Table 104. MeiraGTx Limited Recent Development Table 105. F. Hoffmann-La Roche Company Information Table 106. F. Hoffmann-La Roche Business Overview Table 107. F. Hoffmann-La Roche Long-acting Retinal Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 108. F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio Table 109. F. Hoffmann-La Roche Recent Development Table 110. Bausch Health Co. Inc. Company Information Table 111. Bausch Health Co. Inc. Business Overview Table 112. Bausch Health Co. Inc. Long-acting Retinal Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 113. Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio Table 114. Bausch Health Co. Inc. Recent Development Table 115. Allergan Company Information Table 116. Allergan Business Overview Table 117. Allergan Long-acting Retinal Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 118. Allergan Long-acting Retinal Drugs Product Portfolio Table 119. Allergan Recent Development Table 120. Alimera Sciences Inc. Company Information Table 121. Alimera Sciences Inc. Business Overview Table 122. Alimera Sciences Inc. Long-acting Retinal Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 123. Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio Table 124. Alimera Sciences Inc. Recent Development Table 125. Research Programs/Design for This Report Table 126. Authors List of This Report Table 127. Secondary Sources Table 128. Primary Sources List of Figures Figure 1. Long-acting Retinal Drugs Product Image Figure 2. Global Long-acting Retinal Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-acting Retinal Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-acting Retinal Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Chemically Synthesized Drugs Image Figure 8. Biologics Image Figure 9. Natural/Nutritional Supplements Image Figure 10. Global Long-acting Retinal Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Long-acting Retinal Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Long-acting Retinal Drugs Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Clinic Image Figure 15. Other Image Figure 16. Global Long-acting Retinal Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Long-acting Retinal Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Long-acting Retinal Drugs Sales Value Share by Application (2021-2032) Figure 19. Global Long-acting Retinal Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Long-acting Retinal Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Long-acting Retinal Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. North America Long-acting Retinal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Long-acting Retinal Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Long-acting Retinal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Long-acting Retinal Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Long-acting Retinal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Long-acting Retinal Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. South America Long-acting Retinal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Long-acting Retinal Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Long-acting Retinal Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Chemically Synthesized Drugs
  • Biologics
  • Natural/Nutritional Supplements
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Takeda
  • Teva Pharmaceutical
  • Novartis
  • Merck
  • Bayer
  • Alcon Inc.
  • AbbVie Inc.
  • ThromboGenics
  • Regeneron
  • Oxurion NV
  • OncoGene Pharmaceuticals
  • MeiraGTx Limited
  • F. Hoffmann-La Roche
  • Bausch Health Co. Inc.
  • Allergan
  • Alimera Sciences Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-acting Retinal Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-acting Retinal Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Long-acting Retinal Drugs Market Dynamics
  1. 2.1 Long-acting Retinal Drugs Industry Trends
  2. 2.2 Long-acting Retinal Drugs Industry Drivers
  3. 2.3 Long-acting Retinal Drugs Industry Opportunities and Challenges
  4. 2.4 Long-acting Retinal Drugs Industry Restraints
3 Long-acting Retinal Drugs Market by Company
  1. 3.1 Global Long-acting Retinal Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Long-acting Retinal Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Long-acting Retinal Drugs Company Ranking (2024-2026)
  4. 3.4 Global Long-acting Retinal Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Long-acting Retinal Drugs Company Product Type and Application
  6. 3.6 Global Long-acting Retinal Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Long-acting Retinal Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Long-acting Retinal Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Long-acting Retinal Drugs Market by Type
  1. 4.1 Long-acting Retinal Drugs Type Introduction
  2. 4.1.1 Chemically Synthesized Drugs
  3. 4.1.2 Biologics
  4. 4.1.3 Natural/Nutritional Supplements
  5. 4.2 Global Long-acting Retinal Drugs Sales Value by Type
  6. 4.2.1 Global Long-acting Retinal Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Long-acting Retinal Drugs Sales Value by Type (2021-2032)
  8. 4.2.3 Global Long-acting Retinal Drugs Sales Value Share by Type (2021-2032)
5 Long-acting Retinal Drugs Market by Application
  1. 5.1 Long-acting Retinal Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Long-acting Retinal Drugs Sales Value by Application
  6. 5.2.1 Global Long-acting Retinal Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-acting Retinal Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Long-acting Retinal Drugs Sales Value Share by Application (2021-2032)
6 Long-acting Retinal Drugs Regional Value Analysis
  1. 6.1 Global Long-acting Retinal Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-acting Retinal Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Long-acting Retinal Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Long-acting Retinal Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-acting Retinal Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Long-acting Retinal Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Long-acting Retinal Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Long-acting Retinal Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Long-acting Retinal Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Long-acting Retinal Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Long-acting Retinal Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Long-acting Retinal Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Long-acting Retinal Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Long-acting Retinal Drugs Sales Value Share by Country, 2025 VS 2032
7 Long-acting Retinal Drugs Country-level Value Analysis
  1. 7.1 Global Long-acting Retinal Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-acting Retinal Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Long-acting Retinal Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Long-acting Retinal Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Long-acting Retinal Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Long-acting Retinal Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Long-acting Retinal Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Janssen Pharmaceuticals (Johnson & Johnson)
  2. 8.1.1 Janssen Pharmaceuticals (Johnson & Johnson) Company Information
  3. 8.1.2 Janssen Pharmaceuticals (Johnson & Johnson) Business Overview
  4. 8.1.3 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Janssen Pharmaceuticals (Johnson & Johnson) Long-acting Retinal Drugs Product Portfolio
  6. 8.1.5 Janssen Pharmaceuticals (Johnson & Johnson) Recent Developments
  7. 8.2 Takeda
  8. 8.2.1 Takeda Company Information
  9. 8.2.2 Takeda Business Overview
  10. 8.2.3 Takeda Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Long-acting Retinal Drugs Product Portfolio
  12. 8.2.5 Takeda Recent Developments
  13. 8.3 Teva Pharmaceutical
  14. 8.3.1 Teva Pharmaceutical Company Information
  15. 8.3.2 Teva Pharmaceutical Business Overview
  16. 8.3.3 Teva Pharmaceutical Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva Pharmaceutical Long-acting Retinal Drugs Product Portfolio
  18. 8.3.5 Teva Pharmaceutical Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Long-acting Retinal Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Merck
  26. 8.5.1 Merck Company Information
  27. 8.5.2 Merck Business Overview
  28. 8.5.3 Merck Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Merck Long-acting Retinal Drugs Product Portfolio
  30. 8.5.5 Merck Recent Developments
  31. 8.6 Bayer
  32. 8.6.1 Bayer Company Information
  33. 8.6.2 Bayer Business Overview
  34. 8.6.3 Bayer Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Bayer Long-acting Retinal Drugs Product Portfolio
  36. 8.6.5 Bayer Recent Developments
  37. 8.7 Alcon Inc.
  38. 8.7.1 Alcon Inc. Company Information
  39. 8.7.2 Alcon Inc. Business Overview
  40. 8.7.3 Alcon Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Alcon Inc. Long-acting Retinal Drugs Product Portfolio
  42. 8.7.5 Alcon Inc. Recent Developments
  43. 8.8 AbbVie Inc.
  44. 8.8.1 AbbVie Inc. Company Information
  45. 8.8.2 AbbVie Inc. Business Overview
  46. 8.8.3 AbbVie Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 AbbVie Inc. Long-acting Retinal Drugs Product Portfolio
  48. 8.8.5 AbbVie Inc. Recent Developments
  49. 8.9 ThromboGenics
  50. 8.9.1 ThromboGenics Company Information
  51. 8.9.2 ThromboGenics Business Overview
  52. 8.9.3 ThromboGenics Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 ThromboGenics Long-acting Retinal Drugs Product Portfolio
  54. 8.9.5 ThromboGenics Recent Developments
  55. 8.10 Regeneron
  56. 8.10.1 Regeneron Company Information
  57. 8.10.2 Regeneron Business Overview
  58. 8.10.3 Regeneron Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Regeneron Long-acting Retinal Drugs Product Portfolio
  60. 8.10.5 Regeneron Recent Developments
  61. 8.11 Oxurion NV
  62. 8.11.1 Oxurion NV Company Information
  63. 8.11.2 Oxurion NV Business Overview
  64. 8.11.3 Oxurion NV Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Oxurion NV Long-acting Retinal Drugs Product Portfolio
  66. 8.11.5 Oxurion NV Recent Developments
  67. 8.12 OncoGene Pharmaceuticals
  68. 8.12.1 OncoGene Pharmaceuticals Company Information
  69. 8.12.2 OncoGene Pharmaceuticals Business Overview
  70. 8.12.3 OncoGene Pharmaceuticals Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 OncoGene Pharmaceuticals Long-acting Retinal Drugs Product Portfolio
  72. 8.12.5 OncoGene Pharmaceuticals Recent Developments
  73. 8.13 MeiraGTx Limited
  74. 8.13.1 MeiraGTx Limited Company Information
  75. 8.13.2 MeiraGTx Limited Business Overview
  76. 8.13.3 MeiraGTx Limited Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 MeiraGTx Limited Long-acting Retinal Drugs Product Portfolio
  78. 8.13.5 MeiraGTx Limited Recent Developments
  79. 8.14 F. Hoffmann-La Roche
  80. 8.14.1 F. Hoffmann-La Roche Company Information
  81. 8.14.2 F. Hoffmann-La Roche Business Overview
  82. 8.14.3 F. Hoffmann-La Roche Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 F. Hoffmann-La Roche Long-acting Retinal Drugs Product Portfolio
  84. 8.14.5 F. Hoffmann-La Roche Recent Developments
  85. 8.15 Bausch Health Co. Inc.
  86. 8.15.1 Bausch Health Co. Inc. Company Information
  87. 8.15.2 Bausch Health Co. Inc. Business Overview
  88. 8.15.3 Bausch Health Co. Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bausch Health Co. Inc. Long-acting Retinal Drugs Product Portfolio
  90. 8.15.5 Bausch Health Co. Inc. Recent Developments
  91. 8.16 Allergan
  92. 8.16.1 Allergan Company Information
  93. 8.16.2 Allergan Business Overview
  94. 8.16.3 Allergan Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Allergan Long-acting Retinal Drugs Product Portfolio
  96. 8.16.5 Allergan Recent Developments
  97. 8.17 Alimera Sciences Inc.
  98. 8.17.1 Alimera Sciences Inc. Company Information
  99. 8.17.2 Alimera Sciences Inc. Business Overview
  100. 8.17.3 Alimera Sciences Inc. Long-acting Retinal Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Alimera Sciences Inc. Long-acting Retinal Drugs Product Portfolio
  102. 8.17.5 Alimera Sciences Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst